← Product Code [OOE](/submissions/OP/subpart-e%E2%80%94surgical-devices/OOE) · K123859 # TBD (K123859) _Lensar, Inc. · OOE · Mar 27, 2013 · Ophthalmic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/OOE/K123859 ## Device Facts - **Applicant:** Lensar, Inc. - **Product Code:** [OOE](/submissions/OP/subpart-e%E2%80%94surgical-devices/OOE.md) - **Decision Date:** Mar 27, 2013 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 886.4390 - **Device Class:** Class 2 - **Review Panel:** Ophthalmic - **Attributes:** Therapeutic ## Intended Use The LENSAR Laser System - fs 3D (LLS-fs 3D) is intended for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, laser phacofragmentation, and the creation of full and partial thickness single-plane and multi-plane arc cuts/incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure. ## Device Story Ophthalmic surgical laser system; uses femtosecond laser to perform anterior capsulotomy, phacofragmentation, and corneal incisions. Input: biometric data from 3D optical surface model of eye. Operation: system uses biometric camera and laser to perform 'Localized Imaging'—placing low-energy mark in corneal stroma to measure position relative to anterior/posterior surfaces; system calculates offsets/tilt to ensure accurate laser beam placement despite eye movement. Output: laser-generated corneal incisions and lens fragmentation. Used in clinical setting by ophthalmologists. Benefits: improved accuracy/precision of corneal incision depth compared to manual diamond blade techniques; reduces risk of incorrect placement. ## Clinical Evidence Bench testing only. Porcine ex vivo eye model compared laser-generated partial thickness incisions (PTIs) to manual diamond blade incisions. Results: laser PTIs showed higher depth accuracy (closer to 600um target) and precision than manual. Human donor globe testing confirmed similar mean error and variance. Endothelial cell density evaluation showed no loss when residual corneal bed >85um. ## Technological Characteristics Femtosecond laser system; pulse energy control/monitoring; biometric system with 3D optical surface modeling; localized imaging feedback loop. Connectivity: integrated system. Software: modified for custom shot patterns and self-correcting feedback. Sterilization: not specified. ## Regulatory Identification An ophthalmic laser is an AC-powered device intended to coagulate or cut tissue of the eye, orbit, or surrounding skin by a laser beam. ## Predicate Devices - LENSAR Laser System - fs 3D ([K122829](/device/K122829.md)) - LENSAR Laser System - fs 3D ([K120214](/device/K120214.md)) - LenSx 550 Laser System ([K101626](/device/K101626.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # 510(K) SUMMARY MAR 2 7 2013 This 510(k) summary is being submitted in accordance with the requirements of 21 CFR 807.92(a). ### SUBMITTER'S NAME. ADDRESS, TELEPHONE NUMBER, CONTACT PERSON, AND DATE SUMMARY PREPARED a. Applicant: D LENSAR, Inc. 2800 Discovery Drive, Suite 100 Orlando, FL 32826 Tel: (888) 536-7271 Fax: (407) 386-7228 b. Contact Person: S.K. McGarvey Regulatory Consultant skmcgg@aol.com Cell: (702) 524-3701 Fax: (407) 386-7228 #### DATE SUMMARY PREPARED: December 12, 2012 #### NAME OF DEVICE, INCLUDING TRADE NAME AND CLASSIFICATION NAME - LENSAR Laser System fs 3D (LLS-fs 3D) a. Trade/Proprietary Name: - b. Common/Usual Name: LENSAR Laser System - fs 3D (LLS-fs 3D) - Ophthalmic Laser, Phacofragmentation System C. Classification Name: - 21 CFR 886.4390 OOE; 21 CFR 886.4670 HOC d. Classification Code(s): #### PREDICATE DEVICES | 510(K) # | TRADE NAME | MANUFACTURER | |----------|-----------------------------|----------------------------| | K122829 | LENSAR Laser System - fs 3D | LENSAR, Inc. | | K120214 | LENSAR Laser System - fs 3D | LENSAR, Inc. | | K101626 | LenSx 550 Laser System | LenSx Lasers, Inc. (Alcon) | #### DEVICE DESCRIPTION The predicate LENSAR Laser System is an ophthalmic surgical laser that has been cleared by the Agency for use in anterior capsulotomy and laser phaco fragmentation in cataract surgery performed individually or consecutively during the same surgery under K120214 (LENSAR Laser System - fs 3D). In K122829, the laser expands the Indication for Use to single-plane and multi-plane clear corneal cuts/incisions. This expansion of the {1}------------------------------------------------ Indication for Use is for partial as well as full thickness single-plane and multi-plane arc cuts/incisions in the cornea. The current LLS-fs 3D uses the same laser and the same beam guidance system to deliver laser pulses to the eye as the predicate LENSAR device cleared via 510(k) K120214 and K 122829. Also, the patient interface device (PID), controlled force docking mechanism and moveable optical head to dock the laser to the stationary patient are unchanged from that 510(k) K120214 and K122829. The LLS-fs 3D biometric system, which measures and constructs a three dimensional model of the optical surfaces within the eye, is unchanged from the predicate device except for software modifications to allow the system to analyze the shape and position of the peripheral cornea. To improve the accuracy of incision placement in the cornea, a new functionality called "Localized Imaging" has been added to the system. Localized Imaging is a process whereby the biometric camera is positioned to observe the corneal incision site and a very small laser mark (at low energy) is made at the center of the stroma. By imaging and measuring the position of the mark relative to the cornea anterior and posterior surfaces, the system mitigates any potential of incorrect laser beam placement due to eve movement. The corneal incision surgery is performed immediately after Localized Imaging and results in accurate incision depth in the cornea (<75 microns error). The Indication for Use was expanded to include creation of the corneal incisions for entry to the eye in cataract surgery in K122829 and is now further expanded to include partial thickness corneal arc cuts/incisions. #### STATEMENT OF INTENDED USE The LENSAR Laser System - fs 3D (LLS-fs 3D) is intended for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, laser phacofragmentation, and the creation of full and partial thickness single-plane and multi-plane arc cuts/incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure. #### TECHNOLOGICAL CHARACTERISTICS COMPARISON The femtosecond laser system, including pulse energy control and monitoring, used in the current LLS-fs 3D is the same as that used in the predicate device cleared in K120214 and K122829. The primary difference between the current LENSAR Laser System - fs 3D device and the predicate device is the addition of software for the indication of partial ' thickness single-plane and multi-plane arc cuts/incisions in the cornea for cataract surgery. In the predicate device, the biometric system measured the shape and position of the central cornea for use in the ray tracing necessary to correctly place laser incisions within the crystalline lens. In the current device, corneal measurements are also used to generate custom shot patterns for the corneal incisions. In addition, the current device implements {2}------------------------------------------------ Localized Imaging to make the corneal incisions more accurate, the system now images before and after making laser mark(s) and analyzes the images to apply any offsets or tilt in the intended mark position(s) to the subsequent corneal incisions. Both systems are now integrated to provide self-correcting feedback. | 510(k) Number | Clearance Date | Device Description | |---------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------| | K122829 | 12/03/2012 | LENSAR Laser System - fs 3D (LLS-fs 3D) for creation
of single-plane and multi-plane cuts/ incisions in the
cornea. | | K120214 | 06/08/2012 | LENSAR Laser System - fs 3D (LLS-fs 3D) for anterior
capsulotomy and laser phacofragmentation | | K101626 | 10/18/2010 | LenSx Laser System for anterior capsulotomy,
phacofragmentation, and creation of single-plane and
multi-plane arc cuts/incisions in the cornea | The LLS-fs 3D is of comparable type and is substantially equivalent to the following predicate devices: - . The activities used to evaluate the LENSAR Laser System - fs 3D (LLS-fs 3D) and the information and reports provided in this 510(k) submission do not identify any new issues of safety or effectiveness. The optical radiation hazard analysis confirms the continuing ocular safety and the equivalence to the predicate device detailed in 510(k) K120214 and K122829. - . The LLS-fs 3D laser technology and mechanism of laser-tissue interaction are unchanged from that of the femtosecond laser cleared under K120214 and K122829. - The Indication for Use statement for anterior capsulotomy and laser . phacofragmentation for the LLS-fs 3D is the same as that of the predicate 510(k)cleared LENSAR Laser System - fs 3D (K120214) and the indication for use statement for corneal cuts/incisions in the cornea is the same as that for the LENSAR Laser System - fs 3D (K122829). The indication for use statement for corneal are cuts/incisions in the cornea is the same as that for the LenSx Laser (K101626). - . The differences between the modified LLS-fs 3D and the predicate devices are insignificant and do not affect the safety or effectiveness of the device. ## BRIEF SUMMARY OF PERFORMANCE TEST RESULTS The performance data supporting substantial equivalence of the LENSAR Laser System fs 3D to the predicate LENSAR device is summarized as follows: - . An analysis of the optical radiation hazard to non-target tissue demonstrated that the current LLS-fs 3D femtosecond laser, biometric system scanning diode light source, and patient eye illumination (light emitting diodes) are eye safe under all normal operating and known fault conditions. {3}------------------------------------------------ - A hazard analysis of all potential hazards to the patient, surgeon and other system . operators was performed to consider all changes between the current LLS-fs 3D and predicate LLS-fs 3D device. The hazard analysis demonstrates that all potential hazards have acceptable levels of probability/severity characteristics. - . The accuracy of the depth of conventional manual versus laser-generated partial thickness corneal incisions (PTIs) was tested using a porcine ex vivo eye model. The depths of the incisions were measured using an optical coherence tomographer. A comparison of the depth accuracy of manual and laser PTIs demonstrated that the laser PTIs had measured depths much closer to the target 600 um depth than the manually-created PTIs. - . The laser PTIs in porcine eyes were compared to a smaller number of laser PTIs in human donor globes. The results showed that the mean errors in target accuracy were not different and the variance of the error in incision depth was also about the same. - . Overall, the testing showed that PT's created by the LLS-fs 3D were more accurate and precise than those made using a diamond blade with the conventional manual technique. - · Evaluation of the effect of the laser partial thickness incisions on endothelial cells of ex vivo eyes showed that the laser method resulted in no loss of endothelial cell density when the residual corneal bed is maintained at >85um. - The addition of partial thickness arc cuts/incisions did not result in additional . hazards although the probabilities and severities of some of the hazards identified for the predicate device were changed. Based on the above supportive documentation, the LENSAR Laser System - fs 3D with modified software to permit partial thickness corneal arc cuts/incisions in cataract surgery is substantially equivalent to the LENSAR Laser for anterior capsulotomy and cataract fragmentation (K120214), and full thickness single-plane and multi-plane clear corneal incisions (K122829) with respect to technological characteristics, and to the LenSx Laser (K101626) for the indication for use in corneal arc cuts/incisions. {4}------------------------------------------------ DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines representing its body and wings. The eagle is facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle. Public Health Service March 27, 2013 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 LensAR, Inc. % Ms. S.K. McGarvey Regulatory Consultant 2800 Discovery Drive, Suite 100 Orlando, FL 32826 Re: K123859 Trade/Device Name: Lensar Laser System- fs 3D (LLS-fs 3D) Regulation Number: 21 CFR 886.4390 Regulation Name: Ophthalmic Femtosecond Laser Regulatory Class: Class II Product Code: OOE, HOF Dated: February 8, 2013 Received: February 14, 2013 Dear Ms. McGarvey: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 {5}------------------------------------------------ Page 2 - Ms. S.K. McGarvey CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Kesia YAlexander -S for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {6}------------------------------------------------ # Indications for Use 510(k) Number (if known): K123859 Device Name: LENSAR Laser System - fs 3D (LLS-fs 3D) Indications For Use: The LENSAR Laser System - fs 3D (LLS-fs 3D) is intended for use in patients undergoing cataract surgery for removal of the crystalline lens. Intended uses in cataract surgery include anterior capsulotomy, laser phacofragmentation, and the creation of full and partial thickness single-plane and multi-plane arc cuts/ incisions in the cornea, each of which may be performed either individually or consecutively during the same procedure. Prescription Use الااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااااا (part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Leonid Livshitz 2013.03.21 16:50:40-04'00' (Division Sign-Off) Division of Ophthalmic and Ear, Nose, and Throat Devices 510(k) Number: K 123859 Page 1 of --- **Source:** [https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/OOE/K123859](https://fda.innolitics.com/submissions/OP/subpart-e%E2%80%94surgical-devices/OOE/K123859) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com